Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment

Paclitaxel (PTX) injection (i.e., Taxol) has been used as an effective chemotherapeutic treatment for various cancers. However, the current Taxol formulation contains Cremophor EL, which causes hypersensitivity reactions during intravenous administration and precipitation by aqueous dilution. This c...

Full description

Saved in:
Bibliographic Details
Main Authors: Chowdhury, M.R., Moshikur, R.M., Wakabayashi, R., Tahara, Y., Kamiya, N., Moniruzzaman, M., Goto, M.
Format: Article
Published: American Chemical Society 2018
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047431364&doi=10.1021%2facs.molpharmaceut.8b00305&partnerID=40&md5=1686ee767f2f2e0a8b5ead1d550a6ca9
http://eprints.utp.edu.my/20856/
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.utp.eprints.20856
record_format eprints
spelling my.utp.eprints.208562019-02-26T02:32:32Z Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment Chowdhury, M.R. Moshikur, R.M. Wakabayashi, R. Tahara, Y. Kamiya, N. Moniruzzaman, M. Goto, M. Paclitaxel (PTX) injection (i.e., Taxol) has been used as an effective chemotherapeutic treatment for various cancers. However, the current Taxol formulation contains Cremophor EL, which causes hypersensitivity reactions during intravenous administration and precipitation by aqueous dilution. This communication reports the preliminary results on the ionic liquid (IL)-based PTX formulations developed to address the aforementioned issues. The formulations were composed of PTX/cholinium amino acid ILs/ethanol/Tween-80/water. A significant enhancement in the solubility of PTX was observed with considerable correlation with the density and viscosity of the ILs, and with the side chain of the amino acids used as anions in the ILs. Moreover, the formulations were stable for up to 3 months. The driving force for the stability of the formulation was hypothesized to be the involvement of different types of interactions between the IL and PTX. In vitro cytotoxicity and antitumor activity of the IL-based formulations were evaluated on HeLa cells. The IL vehicles without PTX were found to be less cytotoxic than Taxol, while both the IL-based PTX formulation and Taxol exhibited similar antitumor activity. Finally, in vitro hypersensitivity reactions were evaluated on THP-1 cells and found to be significantly lower with the IL-based formulation than Taxol. This study demonstrated that specially designed ILs could provide a potentially safer alternative to Cremophor EL as an effective PTX formulation for cancer treatment giving fewer hypersensitivity reactions. © 2018 American Chemical Society. American Chemical Society 2018 Article NonPeerReviewed https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047431364&doi=10.1021%2facs.molpharmaceut.8b00305&partnerID=40&md5=1686ee767f2f2e0a8b5ead1d550a6ca9 Chowdhury, M.R. and Moshikur, R.M. and Wakabayashi, R. and Tahara, Y. and Kamiya, N. and Moniruzzaman, M. and Goto, M. (2018) Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment. Molecular Pharmaceutics, 15 (6). pp. 2484-2488. http://eprints.utp.edu.my/20856/
institution Universiti Teknologi Petronas
building UTP Resource Centre
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Teknologi Petronas
content_source UTP Institutional Repository
url_provider http://eprints.utp.edu.my/
description Paclitaxel (PTX) injection (i.e., Taxol) has been used as an effective chemotherapeutic treatment for various cancers. However, the current Taxol formulation contains Cremophor EL, which causes hypersensitivity reactions during intravenous administration and precipitation by aqueous dilution. This communication reports the preliminary results on the ionic liquid (IL)-based PTX formulations developed to address the aforementioned issues. The formulations were composed of PTX/cholinium amino acid ILs/ethanol/Tween-80/water. A significant enhancement in the solubility of PTX was observed with considerable correlation with the density and viscosity of the ILs, and with the side chain of the amino acids used as anions in the ILs. Moreover, the formulations were stable for up to 3 months. The driving force for the stability of the formulation was hypothesized to be the involvement of different types of interactions between the IL and PTX. In vitro cytotoxicity and antitumor activity of the IL-based formulations were evaluated on HeLa cells. The IL vehicles without PTX were found to be less cytotoxic than Taxol, while both the IL-based PTX formulation and Taxol exhibited similar antitumor activity. Finally, in vitro hypersensitivity reactions were evaluated on THP-1 cells and found to be significantly lower with the IL-based formulation than Taxol. This study demonstrated that specially designed ILs could provide a potentially safer alternative to Cremophor EL as an effective PTX formulation for cancer treatment giving fewer hypersensitivity reactions. © 2018 American Chemical Society.
format Article
author Chowdhury, M.R.
Moshikur, R.M.
Wakabayashi, R.
Tahara, Y.
Kamiya, N.
Moniruzzaman, M.
Goto, M.
spellingShingle Chowdhury, M.R.
Moshikur, R.M.
Wakabayashi, R.
Tahara, Y.
Kamiya, N.
Moniruzzaman, M.
Goto, M.
Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment
author_facet Chowdhury, M.R.
Moshikur, R.M.
Wakabayashi, R.
Tahara, Y.
Kamiya, N.
Moniruzzaman, M.
Goto, M.
author_sort Chowdhury, M.R.
title Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment
title_short Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment
title_full Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment
title_fullStr Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment
title_full_unstemmed Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment
title_sort ionic-liquid-based paclitaxel preparation: a new potential formulation for cancer treatment
publisher American Chemical Society
publishDate 2018
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047431364&doi=10.1021%2facs.molpharmaceut.8b00305&partnerID=40&md5=1686ee767f2f2e0a8b5ead1d550a6ca9
http://eprints.utp.edu.my/20856/
_version_ 1738656242367201280
score 13.211869